Meeting
2020 Gastrointestinal Cancers Symposium
Treatment of metastatic colorectal cancer (mCRC) according to age.
Authors
Laura Ortega
Hospital General Universitario Gregorio Marañón, Instituto De Investigacion Sanitaria Gregorio Marañon, Madrid, Spain
Laura Ortega , Gabriela Torres Pérez-Solero , Marta Arregui Valles , Manuel Alva Bianchi , Inmaculada Aparicio Salcedo , Gonzalo García González , Iria Gallego Gallego , Andres J. Muñoz Martín , Aitana Calvo Ferrándiz , Montserrat Blanco-Codesido , Miguel Martin , Pilar Garcia-Alfonso
Disclaimer
This material on this page is ©2024 American Society of Clinical Oncology, all rights reserved. Licensing available upon request. For more information, please contact licensing@asco.org
Poster Details
Session Type
Poster Session
Session Title
Poster Session C: Anal and Colorectal Cancer
Track
Colorectal Cancer,Anal Cancer
Sub Track
Patient-Reported Outcomes and Real-World Evidence
Citation
J Clin Oncol 38, 2020 (suppl 4; abstr 49)
Abstract #
49
Poster Bd #
B21
Abstract Disclosures
Similar Posters
Poster
2011 ASCO Annual Meeting
Phase II study of panitumumab with irinotecan for patients with KRAS wild-type metastatic colorectal cancer (MCRC) refractory to standard chemotherapy: A GERCOR study.
First Author: B. Chibaudel
Poster
2023 ASCO Gastrointestinal Cancers Symposium
Efficacy and safety of fruquintinib plus mFOLFOX6/FOLFIRI as first-line therapy in advanced metastatic colorectal cancer (mCRC).
First Author: Fuxiang Zhou
Poster
2018 ASCO Annual Meeting
Impact of primary tumor side on outcomes of every-2-weeks (q2w) cetuximab + first-line FOLFOX or FOLFIRI in patients with RAS wild-type (wt) metastatic colorectal cancer (mCRC) in the phase 2 APEC trial.
First Author: Timothy Jay Price
Poster
2016 ASCO Annual Meeting
MAVERICC, a phase II study of mFOLFOX6-bevacizumab (BV) vs FOLFIRI-BV as first-line (1L) chemotherapy (CT) in patients (pts) with metastatic colorectal cancer (mCRC): Outcomes by tumor location and KRAS status.
First Author: Heinz-Josef Lenz